|
US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
|
US6657103B1
(en)
|
1990-01-12 |
2003-12-02 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5344760A
(en)
|
1991-06-03 |
1994-09-06 |
Ciba Corning Diagnostics Corp. |
Method of cancer detection
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US6983227B1
(en)
|
1995-01-17 |
2006-01-03 |
Intertech Ventures, Ltd. |
Virtual models of complex systems
|
|
US5977322A
(en)
|
1995-06-14 |
1999-11-02 |
The Regents Of The University Of California |
High affinity human antibodies to tumor antigens
|
|
DE69736806T3
(de)
|
1996-03-27 |
2015-10-08 |
Genentech, Inc. |
ErbB3 ANTIKÖRPER
|
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
|
CA2258721C
(en)
|
1996-07-12 |
2014-09-09 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
US20020002276A1
(en)
|
1997-02-10 |
2002-01-03 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
|
GB2336695A
(en)
|
1998-04-20 |
1999-10-27 |
Teamware Group Oy |
Modelling a work process
|
|
KR20010071271A
(ko)
|
1998-05-15 |
2001-07-28 |
존 비. 랜디스 |
방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
|
|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
KR20110008112A
(ko)
|
1999-08-27 |
2011-01-25 |
제넨테크, 인크. |
항-ＥｒｂＢ2 항체 투여 치료 방법
|
|
US7390632B2
(en)
|
1999-09-30 |
2008-06-24 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US20020009740A1
(en)
|
2000-04-14 |
2002-01-24 |
Rima Kaddurah-Daouk |
Methods for drug discovery, disease treatment, and diagnosis using metabolomics
|
|
CA2407556C
(en)
|
2000-05-19 |
2011-06-21 |
Genentech, Inc. |
Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
|
|
US20020119148A1
(en)
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
|
US6871171B1
(en)
|
2000-10-19 |
2005-03-22 |
Optimata Ltd. |
System and methods for optimized drug delivery and progression of diseased and normal cells
|
|
EP1228766A1
(en)
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 phosphorylation by HER3 induces tumor invasion
|
|
AU2002311919B8
(en)
*
|
2001-05-11 |
2007-03-22 |
Ludwig Institute For Cancer Research Ltd |
Specific binding proteins and uses thereof
|
|
US7612042B2
(en)
|
2001-05-31 |
2009-11-03 |
Tumor Biology Investment Group, Inc. |
Methods for inhibiting heregulin and treating cancer
|
|
US7125680B2
(en)
|
2001-07-27 |
2006-10-24 |
The Regents Of The University Of California |
Methods and materials for characterizing and modulating interaction between heregulin and HER3
|
|
US7662374B2
(en)
|
2001-08-03 |
2010-02-16 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies to activated erbB family members and methods of use thereof
|
|
EP1421113A4
(en)
|
2001-08-03 |
2005-04-13 |
Commw Scient Ind Res Org |
SCREENING BASED ON THE CRYSTAL STRUCTURE OF THE EGF RECEPTOR
|
|
EP1283053A1
(en)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
|
PL368458A1
(en)
|
2001-10-19 |
2005-03-21 |
Pharmamar S.A. |
Improved use of antitumoral compound in cancer therapy
|
|
US7415359B2
(en)
|
2001-11-02 |
2008-08-19 |
Gene Network Sciences, Inc. |
Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
|
|
AU2003218600C1
(en)
|
2002-03-26 |
2009-12-17 |
Zensun (Shanghai) Science & Technology Co., Ltd. |
ERBB3 based methods and compositions for treating neoplasms
|
|
US20040248151A1
(en)
|
2002-04-05 |
2004-12-09 |
Ventana Medical Systems, Inc. |
Method for predicting the response to HER2-directed therapy
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US20040229380A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB heterodimers as biomarkers
|
|
AU2003251597A1
(en)
|
2002-06-19 |
2004-01-06 |
Abgenix, Inc. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
|
AU2003244817B2
(en)
|
2002-06-28 |
2010-08-26 |
Domantis Limited |
Antigen-binding immunoglobulin single variable domains and dual-specific constructs
|
|
JP4609930B2
(ja)
|
2002-12-11 |
2011-01-12 |
ベンタナ・メディカル・システムズ・インコーポレーテッド |
Ｈｅｒ−２指向性治療に対する応答を予測する方法
|
|
EP1613205B1
(en)
|
2003-04-01 |
2013-04-24 |
Monogram BioSciences, Inc. |
Erbb surface receptor complexes as biomarkers
|
|
WO2005014618A2
(en)
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
|
EP1664716A4
(en)
|
2003-08-15 |
2008-08-13 |
Smithkline Beecham Corp |
CANCER BIOMARKERS
|
|
US8554486B2
(en)
|
2004-02-20 |
2013-10-08 |
The Mathworks, Inc. |
Method, computer program product, and apparatus for selective memory restoration of a simulation
|
|
ES2425749T3
(es)
|
2004-03-31 |
2013-10-17 |
The General Hospital Corporation |
Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
|
|
BRPI0510716A
(pt)
|
2004-05-05 |
2007-11-20 |
Merrimack Pharmaceuticals Inc |
uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
|
|
ES2537631T3
(es)
|
2004-05-27 |
2015-06-10 |
The Regents Of The University Of Colorado |
Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
|
|
US7794960B2
(en)
|
2004-06-04 |
2010-09-14 |
Glaxosmithkline Llc |
Predictive biomarkers in cancer therapy
|
|
CA2575791A1
(en)
|
2004-08-03 |
2006-02-16 |
Dyax Corp. |
Hk1-binding proteins
|
|
CN101061238B
(zh)
|
2004-08-06 |
2013-11-20 |
健泰科生物技术公司 |
使用生物标志的测定法和方法
|
|
JP2008532476A
(ja)
|
2004-08-12 |
2008-08-21 |
ダイアックス コーポレーション |
複合結合タンパク質
|
|
WO2006044378A2
(en)
|
2004-10-12 |
2006-04-27 |
University Of Iowa Research Foundation |
Rapid computational identification of targets
|
|
WO2006044748A2
(en)
|
2004-10-15 |
2006-04-27 |
Monogram Biosciences, Inc. |
RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
|
|
WO2006063042A2
(en)
|
2004-12-07 |
2006-06-15 |
Genentech, Inc. |
Selecting patients for therapy with a her inhibitor
|
|
US7862995B2
(en)
|
2004-12-10 |
2011-01-04 |
Targeted Molecular Diagnostics |
Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
|
|
CA2599606A1
(en)
|
2005-02-23 |
2006-08-31 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
|
US20060204505A1
(en)
|
2005-03-08 |
2006-09-14 |
Sliwkowski Mark X |
Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
|
|
US20090061422A1
(en)
|
2005-04-19 |
2009-03-05 |
Linke Steven P |
Diagnostic markers of breast cancer treatment and progression and methods of use thereof
|
|
WO2007015935A2
(en)
|
2005-07-29 |
2007-02-08 |
Bayer Healthcare Llc |
Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
|
|
WO2007041502A2
(en)
|
2005-09-30 |
2007-04-12 |
Monogram Biosciences |
Methods for determining responsiveness to cancer therapy
|
|
WO2007039705A1
(en)
|
2005-10-05 |
2007-04-12 |
Astrazeneca Uk Limited |
Method to predict or monitor the response of a patient to an erbb receptor drug
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
WO2007109571A2
(en)
|
2006-03-17 |
2007-09-27 |
Prometheus Laboratories, Inc. |
Methods of predicting and monitoring tyrosine kinase inhibitor therapy
|
|
EP2049568A2
(en)
|
2006-04-07 |
2009-04-22 |
Københavns Universitet |
Erbb receptor-derived peptide fragments
|
|
US8367351B2
(en)
|
2006-05-05 |
2013-02-05 |
Historx, Inc. |
Methods for determining signal transduction activity in tumors
|
|
JP2009544007A
(ja)
|
2006-07-13 |
2009-12-10 |
イェール・ユニバーシティー |
バイオマーカーの細胞内局在性に基づいて癌予後を行う方法
|
|
US20100158894A1
(en)
*
|
2006-09-15 |
2010-06-24 |
Tokai University |
Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same
|
|
WO2008073629A2
(en)
|
2006-11-03 |
2008-06-19 |
Board Of Regents, The University Of Texas System |
Bifunctional predictors of cancer treatment sensitivity and resistance
|
|
EP2097754B2
(en)
|
2006-11-28 |
2018-01-24 |
Daiichi Sankyo Europe GmbH |
Activated her3 as a marker for predicting therapeutic efficacy
|
|
US7825127B2
(en)
|
2006-12-28 |
2010-11-02 |
Takeda Pharmaceutical Company, Limited |
Method for treating cancer
|
|
KR101598229B1
(ko)
|
2007-02-16 |
2016-02-26 |
메리맥 파마슈티컬즈, 인크. |
Ｅｒｂｂ3에 대한 항체 및 이의 용도
|
|
SI2132573T1
(sl)
|
2007-03-02 |
2014-07-31 |
Genentech, Inc. |
Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
|
|
AU2008239594B2
(en)
|
2007-04-13 |
2013-10-24 |
Beth Israel Deaconess Medical Center |
Methods for treating cancer resistant to ErbB therapeutics
|
|
CA2686908A1
(en)
|
2007-05-11 |
2008-11-20 |
Enzon Pharmaceuticals, Inc. |
Rna antagonist compounds for the modulation of her3
|
|
US20090054051A1
(en)
|
2007-08-22 |
2009-02-26 |
James Cavallo |
Attachable Headset for Portable Device
|
|
MX2010011145A
(es)
|
2008-04-11 |
2011-04-11 |
Merrimack Pharmaceuticals Inc |
Enlazadores de la albumina de suero humana y conjugados de la misma.
|
|
WO2010019952A2
(en)
|
2008-08-15 |
2010-02-18 |
Merrimack Pharmaceuticals, Inc. |
Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
|
|
WO2010059315A1
(en)
|
2008-11-18 |
2010-05-27 |
Merrimack Pharmaceuticals, Inc. |
Human serum albumin linkers and conjugates thereof
|
|
EA201200195A1
(ru)
|
2009-08-21 |
2012-12-28 |
Мерримаск Фармасьютикалс, Инк. |
АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ
|
|
AU2010306774A1
(en)
|
2009-10-14 |
2012-05-03 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
|
|
KR101798679B1
(ko)
|
2010-03-11 |
2017-11-16 |
메리맥 파마슈티컬즈, 인크. |
３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
|
|
WO2011139681A1
(en)
|
2010-04-26 |
2011-11-10 |
Merrimack Pharmaceuticals |
Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
|
|
PH12013500064A1
(en)
|
2010-07-09 |
2013-03-11 |
Exelixis Inc |
Combinations of kinase inhibitors for the treatment of cancer
|
|
FR2963868B1
(fr)
|
2010-08-11 |
2012-09-28 |
Valeo Systemes Thermiques |
Echangeur de chaleur comprenant un element chauffant serigraphie
|
|
EP2648753A4
(en)
|
2010-12-10 |
2015-06-24 |
Merrimack Pharmaceuticals Inc |
DOSAGE AND ADMINISTRATION OF BISPECIFIC SCFV CONJUGATES
|
|
CN103547598A
(zh)
|
2011-02-24 |
2014-01-29 |
梅里麦克制药股份有限公司 |
包含抗-erbb3药剂的联合治疗
|
|
US20140134170A1
(en)
*
|
2011-03-11 |
2014-05-15 |
Merrimack Pharmaceuticals, Inc. |
Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
|
|
MX2013010444A
(es)
|
2011-03-15 |
2014-03-21 |
Merrimack Pharmaceuticals Inc |
Superar la resistencia a inhibidores de la via erbb.
|
|
US8476409B2
(en)
|
2011-04-19 |
2013-07-02 |
Merrimack Pharmaceuticals, Inc. |
Bispecific anti-IGF-1R and anti-ErbB3 antibodies
|
|
CN103596592A
(zh)
|
2011-05-06 |
2014-02-19 |
梅里麦克制药股份有限公司 |
用于预防包含抗ErbB3试剂的联合治疗中的毒性药物间相互作用的方法
|
|
AU2012273361A1
(en)
|
2011-06-24 |
2013-03-21 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel
|
|
AU2012275850A1
(en)
|
2011-06-30 |
2013-03-21 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel for treatment of gynecological cancers
|
|
AU2012294326A1
(en)
*
|
2011-08-10 |
2013-03-21 |
Merrimack Pharmaceuticals, Inc. |
Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
|
|
MX2014011925A
(es)
|
2012-04-02 |
2015-05-11 |
Merrimack Pharmaceuticals Inc |
Dosificacion y administracion de anticuerpos monoespecíficos y biespecíficos anti- igf 1r y anti erbb3.
|
|
WO2014036520A1
(en)
|
2012-08-30 |
2014-03-06 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
EP3087394A2
(en)
|
2013-12-27 |
2016-11-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
|
EP3107578A2
(en)
|
2014-02-20 |
2016-12-28 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
|